Clinical Diabetology

10/07/2025

📢 New issue of Clinical Diabetology (Vol. 14, No. 3 / 2025) is now available online!

Dear Readers,

We are pleased to inform you that the latest issue of Clinical Diabetology has just been published. This edition brings together expert commentaries, original research, and systematic reviews on the challenges and advancements in the care of patients with diabetes — including novel therapeutics, digital monitoring, and real-world clinical data. 🧬📊

🔍 Highlights from the table of contents:

🔷 Editorials
🔹 Tirzepatide: Responders vs. Non-Responders
🔹 Imeglimin in Metformin-Intolerant Patients with Type 2 Diabetes: A Clinical Advancement for Real-World Challenges

🔷 Original Articles
🔹 Maternal and Fetal Implications of Gestational Diabetes Mellitus: A Retrospective, Longitudinal Study
🔹 Safety and Efficacy of Imeglimin in Type 2 Diabetes Individuals with Metformin Intolerance: A Case-Control Study
🔹 Assessment of Diabetes Distress and Its Association with Medication Adherence Among Type 2 Diabetes Patients: A Prospective Cross-Sectional Study
🔹 Association Between Glycation Gap and Renal Complications in People with Type 2 Diabetes
🔹 Intermittently Scanned Continuous Glucose Monitoring in Patients with Type 2 Diabetes in the United Arab Emirates: A Retrospective Analysis

🔷 Review Article
🔹 Efficacy and Safety of Bexagliflozin, a Selective Sodium-Glucose Cotransporter-2 Inhibitor, in Type 2 Diabetes: A Systematic Review and Meta-Analysis

🔷 Letters
🔹 Tirzepatide-Induced Weight Loss and Free Triiodothyronine Exhibit a Negative Correlation
🔹 Effect of Tirzepatide on Blood Pressure in Patients with High Salt Intake

📖 Read the full issue here:
👉 https://journals.viamedica.pl/clinical_diabetology

✍️ Submission Guidelines for Authors:
https://journals.viamedica.pl/clinical_diabetology/about/submissions

📬 For inquiries: joanna.tykarska@viamedica.pl

06/05/2025

New issue of Clinical Diabetology Vol. 14 No. 2 (2025) is now available online.

The latest edition presents a wide range of clinical studies, expert recommendations, and case-based insights into type 2 diabetes management.

The issue opens with an editorial:

The Emerging Trend of Managing Type 2 Diabetes with Oral Semaglutide
— Supratik Bhattacharyya
It explores the growing role of oral semaglutide as a convenient and effective option in diabetes care, especially in India.

Key original articles include:
♦ Medication Adherence and Quality of Life Among Type 2 Diabetes Patients: A Cross-Sectional, Observational Study in Eastern India
♦ Effect of Short-Term Basal Insulin Initiation in Newly Diagnosed Type 2 Diabetes on One-Year Glycemic Control: Prospective Cohort, Interventional, Two-Arm Study
♦ A Randomized Controlled Trial of Aloe Vera Versus Thyme Honey Oral Rinse in the Management of Xerostomia in Type 2 Diabetes
♦ Frailty, Medication Adherence, and Glycemic Control in Patients with Type 2 Diabetes: A Cross-Sectional Study Among Metformin- and Non-Metformin-Exposed Groups

Guidelines:
♦ Expert Opinion on Cardio-Renal-Metabolic Approach to Management of Adults with Type 2 Diabetes Mellitus Using Oral Semaglutide: An Indian Perspective

Review articles:
♦ Premeal Load of Macronutrients as an Effective Nutritional Strategy to Control Postprandial Glycemia

Additionally:
♦ Letters, such as Hemifacial Spasm Associated with Severe Hyperglycemia in a Patient with New-Onset Type 2 Diabetes: A Case Report and Review of the Literature

Explore the full issue here:
https://journals.viamedica.pl/clinical_diabetology

24/02/2025

🔬 We’re Now on ResearchGate! 🔬

Great news! Clinical Diabetology is now available on ResearchGate! 🎉

📚 What does this mean for you?
✔️ Easy access to the latest research in diabetes care and management
✔️ Stay updated with groundbreaking studies in diabetology
✔️ Connect & collaborate with experts and researchers worldwide
✔️ Engage in discussions on the latest advancements in diabetes treatment

📌 Check out our profile and follow us:
🔗 https://www.researchgate.net/journal/Clinical-Diabetology-2450-8187

19/12/2024

Reality of Real-World Experience with Oral Semaglutide in Type 2 Diabetes
Oral semaglutide, the first oral GLP-1 receptor agonist (GLP-1 RA), has demonstrated significant efficacy in managing type 2 diabetes (T2D). Approved by the US FDA in 2019, it offers notable advantages in reducing glycated hemoglobin (HbA1c) and body weight.

Key Real-World Findings
🔷 HbA1c Reduction: Global studies report reductions of up to –1.9% at 18 months, with a mean decrease of ~–1.0%. Greater reductions were observed in patients with higher baseline HbA1c​.
🔷 Weight Loss: Consistent weight loss of –2.8 kg to –6.0 kg was achieved, with Indian cohorts showing reductions up to –5.3 kg​.
🔷 Dose Tolerability: Many patients were maintained on 7 mg doses due to tolerability issues, though maximal benefits were evident at 14 mg​.

Clinical Implications
Oral semaglutide provides an effective alternative to injectable GLP-1 RAs, improving adherence due to its oral formulation. Future studies should address its long-term impact on cardiovascular and renal outcomes.

Authors
Awadhesh Kumar Singh, Akriti Singh, Ritu Singh, Jayshree Swain

For detailed findings, access the full publication:
https://journals.viamedica.pl/clinical_diabetology/article/view/103963

30/10/2024

📢 The latest issue of Clinical Diabetology is now available online!

Dear Readers,

We are pleased to announce the publication of the newest issue of Clinical Diabetology, Vol. 13, No. 5 (2024).
In this issue, you’ll find a range of articles addressing essential and timely topics in type 2 diabetes, its complications, and innovative approaches to treatment and diagnosis.

Highlights include:
✅ Research on the coexistence of cortisol excess and type 2 diabetes,
✅ Analysis of pancreatic and hepatic steatosis in women with type 2 diabetes,
✅ Comparative studies on the effectiveness of antidiabetic medications in real-world clinical settings.

Additionally, this issue features literature reviews exploring novel therapeutic approaches and biological mechanisms related to diabetes. 📖

We invite you to explore the full issue here:
👉 https://journals.viamedica.pl/clinical_diabetology/issue/archive?issueId=6410

28/10/2024

Cut-Off Point Value to Evaluate Abnormality of Systolic Deformation Parameters in Patients with Type 2 Diabetes.

Heart failure is a significant risk for people with type 2 diabetes (T2D). This study, published in Clinical Diabetology, evaluates specific cut-off values for systolic deformation parameters, providing new insights into early detection of left ventricular dysfunction in T2D patients. Speckle tracking echocardiography (STE) reveals subclinical heart abnormalities even with normal ejection fraction, helping to better assess cardiac health. 💓

Key findings:
✅ Abnormal global longitudinal strain (GLS) observed in 78.6% of T2D patients (cut-off: -19%)
✅ Significant prevalence of abnormal GLSR (65.1%) and GCSR (60.9%)
✅ STE provides greater sensitivity in detecting early cardiac dysfunction

Read more: https://journals.viamedica.pl/clinical_diabetology/article/view/100784

Authors: Nguyen Trang Nguyen, Anh Vu Nguyen, Van Chi Le, Hoang Thuy Linh Nguyen, Hoa Thi Phu, Anh Tien Hoang

27/09/2024

🌟 The Interplay between Gut Dysbiosis and Diabetic Nephropathy: Implications for Treatment and Management 🌟

🔬 A new study highlights the significant role of the gut microbiome in the pathogenesis of diabetic nephropathy. Gut dysbiosis exacerbates renal dysfunction via increased systemic inflammation and endothelial damage, accelerating disease progression. The authors explore the therapeutic potential of microbiome-targeted interventions in managing diabetic nephropathy.

👉 Read the full article here:
https://journals.viamedica.pl/clinical_diabetology/article/view/102332

Authors: Jay Mehta, Michał Czech, Włodzimierz Bułhak, Marek Kos.

01/08/2024

Adverse Drug Reactions and Prescribing Patterns of Antidiabetic Medications in Type 2 Diabetes Patients: An Observational Ambispective Study 🌟
🔬 Did you know that managing Type 2 Diabetes (T2D) involves a complex interplay of medications that can sometimes lead to adverse drug reactions (ADRs)?

📊 A recent six-month study conducted on 615 T2D patients revealed critical findings about the prescribing patterns and ADRs associated with antidiabetic medications.

💡 Key Highlights:

✅ Prevalence of ADRs: 35.8% of patients experienced at least one ADR.
✅ Gender Differences: Higher occurrence among females (37.6%) compared to males (34.4%).
✅ Commonly Prescribed Medications: Biguanides, followed by DPP-4 inhibitors and thiazolidinediones.
✅ Frequent ADRs: Gastrointestinal disturbances, weakness, and tiredness were the most reported.
👩‍⚕️ The study underscores the importance of vigilant monitoring and the need for optimal treatment strategies to manage ADRs effectively.

👉 Dive deeper into these findings and explore how they can impact clinical practices in the latest issue of "Clinical Diabetology" Vol 13, No 3 (2024).
Read the full article here:
https://journals.viamedica.pl/clinical_diabetology/article/view/100105

03/07/2024

🌟 New Discoveries in Type 2 Diabetes Treatment! 🌟

🔬 Did you know that handgrip strength might be linked to LDL cholesterol levels in patients with type 2 diabetes? The latest research published in Clinical Diabetology, Vol 13, No 3 (2024), brings intriguing findings!

📊 In a study conducted on 68 patients with , it was found that higher relative handgrip strength (RHGS) positively correlates with LDL cholesterol levels (r = 0.349). What does this mean for patients? It suggests that LDL-C levels might affect muscle strength and quality.

🔎 Although the results did not show a correlation between RHGS and levels of triglycerides (TG) or high-density lipoprotein cholesterol (HDL-C), they indicate the need for further research in this area. Surprising? It’s possible that LDL-C is a new factor influencing muscle strength in T2D patients.

💡 These findings could have significant implications for the secondary prevention of cardiovascular diseases in type 2 diabetes patients. Monitoring RHGS could help detect early signs of sarcopenia, especially when using cholesterol-lowering medications.

👉 Want to learn more about these fascinating discoveries? Read the full article in the latest issue of Clinical Diabetology!

📘 https://journals.viamedica.pl/clinical_diabetology/article/view/99322

03/08/2023

Hello,
Please, find out how climate change affects people living with diabetes. See our recent review on the subject and interview with dr Osagie Ebekozien by Healio:
Ospelt E, et al. Clinical Diabetology. 2023; doi:10.5603/DK.a2023.0012 https://journals.viamedica.pl/clinical_diabetology/article/view/DK.a2023.0012

Q&A: Climate change presents special concerns for people with diabetes https://www.healio.com/news/endocrinology/20230801/qa-climate-change-presents-special-concerns-for-people-with-diabetes

Objective: There is substantial literature detailing the interaction between climate change and diabetes incidence, prevalence, and development. However, there is limited understanding on the impact of climate change on People Living with Diabetes (PWD). This scoping review describes the impact of c...

05/06/2023

Dear Authors and Friends of Clinical Diabetology,

We are happy to let you know that one of our major goals in restructuring the Journal formulated one year ago has been reached.
Current average time from manuscript submission to final publication is below 90 days. Please, see details of all our timing components in manuscript flow.

CD Editorial Office